OBJECTIVE: The extent to which noncompletion of a clinical trial relates to outcomes has implications for choosing the most appropriate method for contending with missing data due to dropout. We examined whether dropout relates to outcome in clinical trials of antipsychotic medication. METHODS: Data from 5 large clinical trials of schizophrenia (n=3483) were examined separately. Patients were aggregated into groups based on their final study visit. Group mean Positive and Negative Syndrome Scale (PANSS) total scores for each visit were computed and graphed. Change from baseline to end point for each group was computed and examined using ANCOVA. Cox regression modeling was used to examine baseline PANSS total and change as predictors of time to dropout. RESULTS: In all 5 trials there was a statistically significantly relationship between time in trial and improvement. The longer the patients remained in the trial the more that they improved, with trial completers showing the most improvement at each time point. Higher baseline PANSS scores and symptom deterioration indicated by increased PANSS preceding the final study visit prior to dropout corresponded significantly with a greater likelihood of dropout. CONCLUSIONS: Dropout in clinical trials of antipsychotic medications corresponds with efficacy outcomes, the dynamics of symptom change and baseline symptom severity. Therefore, methods for statistical analysis should examine both efficacy and dropout and cannot assume that missing data due to dropout are completely at random.
OBJECTIVE: The extent to which noncompletion of a clinical trial relates to outcomes has implications for choosing the most appropriate method for contending with missing data due to dropout. We examined whether dropout relates to outcome in clinical trials of antipsychotic medication. METHODS: Data from 5 large clinical trials of schizophrenia (n=3483) were examined separately. Patients were aggregated into groups based on their final study visit. Group mean Positive and Negative Syndrome Scale (PANSS) total scores for each visit were computed and graphed. Change from baseline to end point for each group was computed and examined using ANCOVA. Cox regression modeling was used to examine baseline PANSS total and change as predictors of time to dropout. RESULTS: In all 5 trials there was a statistically significantly relationship between time in trial and improvement. The longer the patients remained in the trial the more that they improved, with trial completers showing the most improvement at each time point. Higher baseline PANSS scores and symptom deterioration indicated by increased PANSS preceding the final study visit prior to dropout corresponded significantly with a greater likelihood of dropout. CONCLUSIONS: Dropout in clinical trials of antipsychotic medications corresponds with efficacy outcomes, the dynamics of symptom change and baseline symptom severity. Therefore, methods for statistical analysis should examine both efficacy and dropout and cannot assume that missing data due to dropout are completely at random.
Authors: Craig H Mallinckrodt; Todd M Sanger; Sanjay Dubé; David J DeBrota; Geert Molenberghs; Raymond J Carroll; William Z Potter; Gary D Tollefson Journal: Biol Psychiatry Date: 2003-04-15 Impact factor: 13.382
Authors: John M Kane; Mariëlle Eerdekens; Jean-Pierre Lindenmayer; Samuel J Keith; Michael Lesem; Keith Karcher Journal: Am J Psychiatry Date: 2003-06 Impact factor: 18.112
Authors: W Wolfgang Fleischhacker; Mariëlle Eerdekens; Keith Karcher; Gary Remington; Pierre-Michel Llorca; Wlodzimierz Chrzanowski; Stephen Martin; Ola Gefvert Journal: J Clin Psychiatry Date: 2003-10 Impact factor: 4.384
Authors: Jeffrey A Lieberman; Gary Tollefson; Mauricio Tohen; Alan I Green; Raquel E Gur; Rene Kahn; Joseph McEvoy; Diana Perkins; Tonmoy Sharma; Robert Zipursky; Hank Wei; Robert M Hamer Journal: Am J Psychiatry Date: 2003-08 Impact factor: 18.112
Authors: Venkatesh Pilla Reddy; Magdalena Kozielska; Martin Johnson; An Vermeulen; Rik de Greef; Jing Liu; Geny M M Groothuis; Meindert Danhof; Johannes H Proost Journal: Clin Pharmacokinet Date: 2011-07 Impact factor: 6.447
Authors: Venkatesh Pilla Reddy; Magdalena Kozielska; Martin Johnson; Ahmed Abbas Suleiman; An Vermeulen; Jing Liu; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost Journal: Clin Pharmacokinet Date: 2012-04-01 Impact factor: 6.447
Authors: Allen W Nyhuis; Douglas E Faries; Haya Ascher-Svanum; Virginia L Stauffer; Bruce J Kinon Journal: BMC Psychiatry Date: 2010-09-28 Impact factor: 3.630